Archive

Rebel Category: REBEL Covid-19

The MICHELLE Trial: Anticoagulation Post-Discharge in Patients Hospitalized Secondary to COVID-19

Background: Patients diagnosed with COVID-19 have an increased risk of thromboembolic events, including pulmonary embolism and deep vein thrombosis (DVT). In addition, COVID-19 patients with increased coagulation parameters such as D-dimer, fibrin degradation products, prothrombin time, and activated partial thromboplastin …

Read More
CardiovascularHematology and OncologyInfectious DiseaseThoracic and Respiratory

The MOVe-Out Trial: Molnupiravir – Oral Antivirals for Management of Covid-19?

Background: On December 23, 2021, the FDA granted molnupiravir emergency use authorization for the treatment of patients with Covid-19. Molnupiravir is a nucleoside analog that inhibits SARS-CoV-2 replication and triggers viral RNA mutagenesis. Until the release of oral antivirals, clinicians …

Read More

The ACTIV-4b Trial: Antithrombotics For Treatment of Outpatient COVID-19

Background: Severely ill patients diagnosed with COVID-19 have an increased risk of cardiovascular complications, especially thromboembolic events (Bikdeli 2020). The overall incidence of developing venous thromboembolism (VTE) is approximately 17% in patients diagnosed with COVID-19, with a significantly higher rate …

Read More
Thoracic and Respiratory

COV-BARRIER Addendum Study: Baricitinib in ECMO/Mechanically Ventilated Patients with COVID-19

Background:  Despite access to vaccines in developed countries, COVID19 remains a nimble and persistent foe. While case counts wax and wane the virus continues to spread and mutate. The rapid development of vaccines has been helpful but the distribution across …

Read More
Infectious DiseaseThoracic and Respiratory

The HEP-COVID Trial: Therapeutic Anticoagulation in Non-Critically Ill COVID-19 Patients

Background: Patients with COVID-19 are at increased risk from thromboembolic phenomena. Patient-specific factors such as comorbidities and immobility have been linked to thrombosis. Disease-specific factors such as virus-induced endothelial changes and cytokine storm may also be triggers. Furthermore, patients with elevated …

Read More
Hematology and OncologyInfectious DiseaseThoracic and Respiratory

Sponsored

0